1) Preclinical Alzheimer disease and 2) Topic of the month: Cerebellar ataxias. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Prof. Michael Ewers about his paper on preclinical Alzheimer disease. Dr. Stacey Clardy is reading our e-Pearl of the week about neurologic symptoms in relapsing polychondritis. In the next part of the podcast Dr. Ted Burns interviews Drs. Susan Perlman and Jeremy Schmahmann about the topic of inherited ataxias and sporadic, degenerative ataxias. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs Jeff Burns, Ewers, Clardy, Ted Burns, Perlman and Schmahmann.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Ewers serves as Senior Editor of Alzheimer's & Dementia and receives compensation for traveling to conferences from the Alzheimer's Association and International College of Geriatric Psychoneuropharmacology.Dr. Clardy served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Perlman serves on Medical Research Advisory Board for the National Ataxia Foundation, receives research support from Santhera Pharmaceuticals, Edison Pharmaceuticals, Friedreich Ataxia Research Alliance, and ARRAS funding via the RDN-CRC.Dr. Schmahmann serves as an editorial board member for The Cerebellum; receives royalties from the publication of the books The cerebellum and cognition, MRI atlas of the human cerrellum and Fiber pathways of the brain; holds stock options in Brother and for legal counsel to Johnson & Johnson; receives research support from Birmingham Foundation MINDlink Foundation Sidney R. Baer Jr., Foundations and the NIH and has a patent pending for transcranial magnetic stimulation.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related